These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19399272)

  • 1. Effect of iron-chelator deferiprone on the in vitro growth of staphylococci.
    Kim CM; Shin SH
    J Korean Med Sci; 2009 Apr; 24(2):289-95. PubMed ID: 19399272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activities of iron chelators against common nosocomial pathogens.
    Thompson MG; Corey BW; Si Y; Craft DW; Zurawski DV
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5419-21. PubMed ID: 22850524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron chelation in chemotherapy.
    Weinberg ED
    Adv Appl Microbiol; 2003; 52():187-208. PubMed ID: 12964245
    [No Abstract]   [Full Text] [Related]  

  • 4. Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats.
    Brissot P; Bolder U; Schteingart CD; Arnaud J; Hofmann AF
    Hepatology; 1997 Jun; 25(6):1457-61. PubMed ID: 9185768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica.
    Lesic B; Foulon J; Carniel E
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1741-5. PubMed ID: 12019084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
    Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
    J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice.
    Eybl V; Kotyzová D; Kolek M; Koutenský J; Nielsen P
    Toxicol Lett; 2002 Mar; 128(1-3):169-75. PubMed ID: 11869827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
    Srichairatanakool S; Thephinlap C; Phisalaphong C; Porter JB; Fucharoen S
    Med Chem; 2007 Sep; 3(5):469-74. PubMed ID: 17897073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
    Emara AM; El Kelany RS; Moustafa KA
    Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferiprone iron chelation as a novel therapy for experimental mucormycosis.
    Ibrahim AS; Edwards JE; Fu Y; Spellberg B
    J Antimicrob Chemother; 2006 Nov; 58(5):1070-3. PubMed ID: 16928702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload.
    al-Refaie FN; De Silva CE; Wonke B; Hoffbrand AV
    J Clin Pathol; 1995 Feb; 48(2):110-4. PubMed ID: 7745107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
    Wongjaikam S; Kumfu S; Khamseekaew J; Sripetchwandee J; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    PLoS One; 2016; 11(7):e0159414. PubMed ID: 27428732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating iron overload: the state of the art.
    Hershko C
    Semin Hematol; 2005 Apr; 42(2 Suppl 1):S2-4. PubMed ID: 15846582
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A; Felisi M; De Sanctis V; De Mattia D
    Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron mobilisation from transferrin by deferiprone (L1).
    Kontoghiorghes GJ; Kolnagou A; Eracleous E; Evans RW
    Br J Haematol; 2005 Apr; 129(1):157. PubMed ID: 15801969
    [No Abstract]   [Full Text] [Related]  

  • 18. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD; Evans RW; Evans PJ; Hider RC
    Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative effect of deferiprone on the Hep G2 cell line.
    Chenoufi N; Drénou B; Loréal O; Pigeon C; Brissot P; Lescoat G
    Biochem Pharmacol; 1998 Aug; 56(4):431-7. PubMed ID: 9763218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of iron chelation on the in-vitro growth of Leishmania promastigotes.
    Soteriadou K; Papavassiliou P; Voyiatzaki C; Boelaert J
    J Antimicrob Chemother; 1995 Jan; 35(1):23-9. PubMed ID: 7768775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.